Journal
JOURNAL OF CLINICAL IMMUNOLOGY
Volume 27, Issue 2, Pages 181-192Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-006-9065-8
Keywords
autoimmunity; enolase; autoantibody; apoptosis; glycolysis; neuroimmunology
Categories
Funding
- NEI NIH HHS [EY13053, R01 EY013053] Funding Source: Medline
Ask authors/readers for more resources
Autoantibodies against alpha-enolase, a glycolytic enzyme, have been frequently associated with visual loss and retinal degeneration in patients with autoimmune and cancer-associated retinopathy; however their role in the pathogenicity of retinopathy has not been fully explained. Thus, we examined the causative role of anti-enolase antibodies on retinal cells. In the in vitro studies reported here, we found that Enol-1 monoclonal antibody against alpha-enolase significantly inhibited the catalytic function of enolase, which resulted in the depletion of glycolytic ATP. Enol-1 significantly increased intracellular Ca2+, which led to Bax translocation to the mitochondria, and the release of cytochrome c into the cytoplasm-events that correlated with the initiation of apoptosis. Normal IgG did not induce intracellular calcium or reduce cytosolic ATP. L-type voltage-gated calcium channel blockers (nifedipine, D-cis-diltiazem, and verapamil) were effective in blocking the Ab-induced intracellular Ca2+ rise and induction of Bax. Based on these findings we propose that chronic access of autoantibodies to the retina results in the inhibition of enolase catalytic function, depletion of ATP, and elevation in intracellular Ca2+, leading to deregulation of glycolysis in retinal neurons and their destruction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available